The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Open accessAbstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. The effectiveness of Trastuzumab has been well validated in research as well as in clinical practice. The addition of Trastuzumab to standard of care chemotherapy in clinical trials has been shown to improve outcomes for early stage as well as metastatic HER2 positive breast cancer. The most clinically significant side effect of Trastuzumab is the risk of cardiac myocyte injury, leading to the development of congestive heart failure. The emergence of patterns of resistance to Trastuzumab has led to the discovery of new monoclonal antibodies and other targeted agents aimed at overcoming Trastuzumab resistance and improving survival in patients diagnosed with HER2 positive breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 2×
“The combination of a taxane-based regimen followed by Trastuzumab appears to cause less cardiac dysfunction [17, 28, 31, 65].”
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Cohn, J. N., Ferrari, R., & Sharpe, N. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00630-0 · Cited by 2,161
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond
Mann, D. L., & Bristow, M. R. (2005) · Circulation · doi:10.1161/circulationaha.104.500546 · Cited by 867
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577 · cited 1×
“to be T-cell mediated, through activation of the FC receptor, leading to increased cell death [18].”
BackgroundUntch, M., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8451 · Cited by 556
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh131 · Cited by 512
Neuregulins Promote Survival and Growth of Cardiac Myocytes
Zhao, Y.-Y., Sawyer, D. R., Baliga, R. R., Opel, D. J., Han, X., Marchionni, M. A., & Kelly, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10261 · Cited by 504
Spector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
Stress Pathways and Heart Failure
Chien, K. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80043-4 · Cited by 446
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 385
Stern, D. F., Heffernan, P. A., & Weinberg, R. A. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.5.1729 · Cited by 327
Fukushige, S., Matsubara, K., Yoshida, M., Sasaki, M., Suzuki, T., Semba, K., Toyoshima, K., & Yamamoto, T. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.3.955 · Cited by 324
Adriamycin cardiomyopathy: pathophysiology and prevention
Singal, P. K., Iliskovic, N., Li, T., & Kumar, D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.12.9337145 · Cited by 310
Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294
Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002) · Circulation · doi:10.1161/01.cir.0000013839.41224.1c · Cited by 292
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6450 · Cited by 255
NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy
Nakagami, H. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00145-7 · Cited by 255
Xia, W., Liu, L.-H., Ho, P., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253
Ewer, M. S., Ali, M. K., Mackay, B., Wallace, S., Valdivieso, M., Legha, S. S., Benjamin, R. S., & Haynie, T. P. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.2.112 · Cited by 244
Procter, M., Suter, T. M., de Azambuja, E., Dafni, U., van Dooren, V., Muehlbauer, S., Climent, M. A., Rechberger, E., Liu, W. T.-W., Toi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0463 · Cited by 244
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes
Grazette, L. P., Boecker, W., Matsui, T., Semigran, M., Force, T. L., Hajjar, R. J., & Rosenzweig, A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.066 · Cited by 241
Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2
Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., & Yoshinaga, S. K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3884 · Cited by 207
Gordon, L. I., Burke, M. A., Singh, A. T. K., Prachand, S., Lieberman, E. D., Sun, L., Naik, T. J., Prasad, S. V. N., & Ardehali, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804570200 · Cited by 185
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.
Zeglinski, M. R., Lüdke, A., Jassal, D. S., & Singal, P. K. (2011) · Europe PMC (PubMed Central) · Cited by 181
Timolati, F., Ott, D., Pentassuglia, L., Giraud, M.-N., Perriard, J.-C., Suter, T. M., & Zuppinger, C. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.08.002 · Cited by 178
Suter, T. M., Cook-Bruns, N., & Barton, C. (2004) · The Breast · doi:10.1016/j.breast.2003.09.002 · Cited by 166
Baselga, J. M., & Swain, S. M. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.065 · Cited by 145
Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy
Meric‐Bernstam, F., & Hung, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1732 · Cited by 129
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Mukohara, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01711.x · Cited by 123
Pierga, J., Delaloge, S., Espié, M., Brain, E. G. C., Sigal‐Zafrani, B., Mathieu, M., Bertheau, P., Jm, G., Spielmann, M., Savignoni, A., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0939-3 · Cited by 105
Pinkas‐Kramarski, R., Lenferink, A. E. G., Bacus, S. S., Lyass, L., van de Poll, M. L. M., Klapper, L. N., Tzahar, E., Sela, M., van Zoelen, E. J. J., & Yarden, Y. (1998) · Oncogene · doi:10.1038/sj.onc.1201642 · Cited by 99
Pituskin, E., Haykowsky, M. J., Mackey, J. R., Thompson, R. B., Ezekowitz, J. A., Koshman, S. L., Oudit, G. Y., Chow, K., Pagano, J. J., & Paterson, D. I. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-318 · Cited by 89
Madarnas, Y., Trudeau, M., Franek, J. A., McCready, D. R., Pritchard, K. I., & Messersmith, H. J. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.013 · Cited by 89
Cardiotoxicity of Trastuzumab in Clinical Practice
McArthur, H. L., & Chia, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070065 · Cited by 85
Limentani, S. A., Brufsky, A., Erban, J. K., Jahanzeb, M., & LEWIS, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3306 · Cited by 85
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, G., Fasolo, A., Benedictis, E. D., & Gianni, L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1298 · Cited by 80
Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer
Ewer, M. S., & O’Shaughnessy, J. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.017 · Cited by 78
Late doxorubicin-associated cardiotoxicity in children
Ali, M. K., Ewer, M. S., Gibbs, H. R., Swafford, J., & Graff, K. L. (1994) · Cancer · Cited by 77
Untch, M., Muscholl, M. W., Tjulandin, S., Jonat, W., Meerpohl, H. G., Lichinitser, M., Manikhas, A., Coumbos, A., Kreienberg, R., du Bois, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9709 · Cited by 72
Pentassuglia, L., Graf, M., Lane, H. A., Kuramochi, Y., Cote, G. M., Timolati, F., Sawyer, D. B., Zuppinger, C., & Suter, T. M. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.02.001 · Cited by 69
Hamberg, P., Bos, M. M. E. M., Braun, H. J. J., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.003 · Cited by 62
Nuti, M., Bellati, F., Visconti, V. V., Napoletano, C., Domenici, L., Caccetta, J., Zizzari, I. G., Ruscito, I., Rahimi, H., Panici, P. B., et al. (2011) · Journal of Cancer · doi:10.7150/jca.2.317 · Cited by 48
Lazaridis, G., Pentheroudakis, G. E., & Pavlidis, N. A. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.002 · Cited by 40
Neuregulin Signaling and Heart Failure
Jiang, Z., & Zhou, M. (2010) · Current Heart Failure Reports · doi:10.1007/s11897-010-0003-y · Cited by 31
The epidermal growth factor receptor family in breast cancer
Koutras, A. K., & Evans, T. R. J. (2008) · OncoTargets and Therapy · doi:10.2147/ott.s3842 · Cited by 24
Cited by
Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Recent advances in biosensor development for the detection of cancer biomarkers
Jayanthi, V. S. P. K. S. A., Das, A. B., & Saxena, U. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.12.014 · Cited by 565
Tian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., Nice, E. C., Xie, N., Huang, C., & Shen, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01320-5 · Cited by 426
Jiang, Q., Liu, Y., Guo, R., Yao, X., Sung, S., Pang, Z., & Yang, W. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.021 · Cited by 398
Metadata
- Authors
- Mitri, Z., Constantine, T., & O'Regan, R.
- Venue
- Chemotherapy Research and Practice
- Publisher
- Wiley
- Published
- 2012-12-20
- Volume
- 2012
- Pages
- 1-7
- ISSN
- 2090-2107 (ISSN-L)
- 2090-2115
- OpenAlex
- W2056839334
- Cited by
- 519
- References
- 83
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.